Abstract
The continued development of computational and synthetic methods has enabled the enumeration or preparation of a nearly endless universe of chemical structures. Nevertheless, the ability of this chemical universe to deliver small molecules that can both modulate biological targets and have drug-like physicochemical properties continues to be a topic of interest to the pharmaceutical industry and academic researchers alike. The chemical space described by public, commercial, in-house and virtual compound collections has been interrogated by multiple approaches including biochemical, cellular and virtual screening, diversity analysis, and in-silico profiling. However, current drugs and known chemical probes derived from these efforts are contained within a remarkably small volume of the predicted chemical space. Access to more diverse classes of chemical scaffolds that maintain the properties relevant for drug discovery is certainly needed to meet the increasing demands for pharmaceutical innovation. The Lilly Open Innovation Drug Discovery platform (OIDD) was designed to tackle barriers to innovation through the identification of novel molecules active in relevant disease biology models. In this article we will discuss several computational approaches towards describing novel, biologically active, drug-like chemical space and illustrate how the OIDD program may facilitate access to previously untapped molecules that may aid in the search for innovative pharmaceuticals.
Keywords: Open innovation, chemical space, drug discovery.
Current Topics in Medicinal Chemistry
Title:Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space
Volume: 14 Issue: 3
Author(s): Maria Alvim-Gaston, Timothy Grese, Abdelaziz Mahoui, Alan D. Palkowitz, Marta Pineiro-Nunez and Ian Watson
Affiliation:
Keywords: Open innovation, chemical space, drug discovery.
Abstract: The continued development of computational and synthetic methods has enabled the enumeration or preparation of a nearly endless universe of chemical structures. Nevertheless, the ability of this chemical universe to deliver small molecules that can both modulate biological targets and have drug-like physicochemical properties continues to be a topic of interest to the pharmaceutical industry and academic researchers alike. The chemical space described by public, commercial, in-house and virtual compound collections has been interrogated by multiple approaches including biochemical, cellular and virtual screening, diversity analysis, and in-silico profiling. However, current drugs and known chemical probes derived from these efforts are contained within a remarkably small volume of the predicted chemical space. Access to more diverse classes of chemical scaffolds that maintain the properties relevant for drug discovery is certainly needed to meet the increasing demands for pharmaceutical innovation. The Lilly Open Innovation Drug Discovery platform (OIDD) was designed to tackle barriers to innovation through the identification of novel molecules active in relevant disease biology models. In this article we will discuss several computational approaches towards describing novel, biologically active, drug-like chemical space and illustrate how the OIDD program may facilitate access to previously untapped molecules that may aid in the search for innovative pharmaceuticals.
Export Options
About this article
Cite this article as:
Alvim-Gaston Maria, Grese Timothy, Mahoui Abdelaziz, Palkowitz D. Alan, Pineiro-Nunez Marta and Watson Ian, Open Innovation Drug Discovery (OIDD): A Potential Path to Novel Therapeutic Chemical Space, Current Topics in Medicinal Chemistry 2014; 14(3) . https://dx.doi.org/10.2174/1568026613666131127125858
DOI https://dx.doi.org/10.2174/1568026613666131127125858 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Antiangiogenic Agents: Studies on Fumagillin and Curcumin Analogs
Current Pharmaceutical Design Characteristics and Outcomes of Children with Type-I Diabetes Mellitus Hospitalized for Ketoacidosis
Current Diabetes Reviews Metformin Protects the Brain Against the Oxidative Imbalance Promoted by Type 2 Diabetes
Medicinal Chemistry The Effect of Licorice Drink on the Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism
Current Drug Metabolism Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib
Current Drug Targets Theranostic Potential of Targeted Nanoparticles for Brain Cancer
Mini-Reviews in Medicinal Chemistry Applications of Cellulose-based Materials in Sustained Drug Delivery Systems
Current Medicinal Chemistry Safety Issues of Vitamin D Supplementation
Anti-Cancer Agents in Medicinal Chemistry Processing of DNA Replication and Repair Intermediates by the Concerted Action of RecQ Helicases and Rad2 Structure-Specific Nucleases
Protein & Peptide Letters Could Polyphenolic Food Intake Help in the Control of Type 2 Diabetes? A Narrative Review of the Last Evidence
Current Nutrition & Food Science The Role of the PACAP Signaling System in Depression
Current Pharmaceutical Design Far-infrared Ray-mediated Antioxidant Potentials are Important for Attenuating Psychotoxic Disorders
Current Neuropharmacology Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Polymer Self-Assembled Nanostructures as Innovative Drug Nanocarrier Platforms
Current Pharmaceutical Design Rimonabant for the Treatment of Obesity
Recent Patents on Cardiovascular Drug Discovery Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry How Similar are Human Mesenchymal Stem Cells Derived from Different Origins? A Review of Comparative Studies
Current Stem Cell Research & Therapy Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design